GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Integrated Biopharma INBP · USD

Consumer Staples · US listing · 🇺🇸 United States

Compare

0.17

+2.94%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$43.9m

FY2017FY2026

Net income

−$2.8m

FY2017FY2026

Free cash flow

$895,000

FY2017FY2026

Shareholders' equity

$17.7m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$43.9m$54.4m$50.3m$50.7m$56.2m$63.6m$52.8m$50.0m$43.7m$47.0m
Gross profit$800,000$5.6m$3.9m$4.1m$7.4m$9.5m$6.7m$6.2m$5.0m$6.7m
Operating income−$2.7m$2.0m$251,000$120,000$2.7m$5.8m$3.3m$2.7m$1.7m$3.2m
Net income−$2.8m$808,000$112,000−$34,000$3.8m$8.0m$4.1m$1.7m$679,000$2.3m
Diluted earnings per share-0.090.030.00-0.000.120.260.130.050.020.08

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$25.3m$24.9m$26.2m$25.4m$25.3m$25.4m$22.9m$19.8m$14.6m$15.2m
Cash and short-term investments—————$210,000$402,000$475,000$228,000$597,000
Total liabilities$7.7m$4.6m$7.0m$6.6m$6.7m$11.1m$16.9m$17.9m$19.8m$21.1m
Debt———$7,000$53,000$3.6m$8.3m$5.8m$5.7m$10.0m
Shareholders' equity$17.7m$20.3m$19.2m$18.9m$18.6m$14.3m$6.1m$1.9m−$5.2m−$5.9m
Shares outstanding31m31m31m31m31m31m31m31m31m31m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations$1.2m$2.1m$943,000$1.2m$4.1m$3.0m$1.3m$328,000$1.2m$397,000
Capital spending−$346,000−$205,000−$553,000−$116,000−$486,000−$295,000−$214,000−$414,000−$247,000−$327,000
Free cash flow$895,000$1.9m$390,000$1.1m$3.6m$2.8m$1.1m−$86,000$921,000$70,000

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$9.8m$10.1m$11.3m$12.7m$14.2m$13.9m$12.6m$13.6m
Gross profit$28,000−$276,000$29,000$1.0m$1.5m$1.6m$1.2m$1.4m
Operating income−$869,000−$1.1m−$914,000$163,000$589,000$739,000$202,000$490,000
Net income−$1.4m−$837,000−$762,000$123,000−$178,000$611,000$116,000$259,000
Diluted earnings per share-0.04-0.03-0.020.00-0.010.020.000.01
Cash from operations−$1.0m——$1.0m————
Total assets$25.3m$26.7m$23.5m$25.5m$24.9m$25.7m$25.7m$26.2m
Shareholders' equity$17.7m$19.0m$19.8m$20.5m$20.3m$20.4m$19.7m$19.6m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-4.7%-7.1%0.4%
Net income337.2%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin6.5%7.2%9.8%11.0%
Operating margin-0.7%-0.2%2.6%3.8%
Net margin-2.1%-1.0%3.1%3.5%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-1.913.791.4-224.02.94.05.64.56.82.4
Price to sales0.10.20.20.10.20.50.40.10.10.1

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-2%27%-31%-62%18%268%52%-21%6%46%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.